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Expression of M. tuberculosis-induced suppressor
of cytokine signaling (SOCS) 1, SOCS3, FoxP3 and
secretion of IL-6 associates with differing clinical
severity of tuberculosis
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Abstract
Background: Appropriate immune activation of T cells and macrophages is central for the control of
Mycobacterium tuberculosis infections. IFN-γ stimulated responses are lowered in tuberculosis (TB), while expression
of Suppressor of Cytokine Signaling (SOCS) molecules – 1 and 3 and CD4+CD25+FoxP3+T regulatory cells is
increased. Here we investigated the association of these molecules in regard to clinical severity of TB.
Methods: Peripheral blood mononuclear cells (PBMCs) were isolated from patients with pulmonary TB (PTB, n = 33),
extra-pulmonary TB (ETB, n = 33) and healthy endemic controls (EC, n = 15). Cases were classified as moderately
advanced or far advanced PTB, and less severe or severe disseminated ETB. M. tuberculosis -stimulated IFN-γ, SOCS1,
SOCS3 and FoxP3 gene expression and secretion of Th1 and Th2 cytokines was measured. Statistical analysis was
performed using Mann–Whitney U, Wilcoxon Rank and Kruskal Wallis non-parametric tests.
Results: In un-stimulated PBMCs, IL-6 (p = 0.018) and IL-10 (p = 0.013) secretion levels were increased in PTB while
IL-10 was also increased in ETB (p = 0.003), all in comparison with EC. M. tuberculosis-stimulated IL-6 (p = 0.003) was
lowered in ETB as compared with EC. SOCS1 mRNA expression in M. tuberculosis stimulated PBMCs levels in
moderately advanced PTB (p = 0.022), far advanced (p = 0.014) PTB, and severe ETB (p = 0.009) were raised as
compared with EC. On the other hand, SOCS1 mRNA titers were reduced in less severe ETB, in comparison with
severe ETB (p = 0.027) and far advanced PTB (p = 0.016). SOCS3 mRNA accumulation was reduced in far advanced
PTB (p = 0.007) and FoxP3 mRNA expression was increased in less severe ETB as compared with EC (p = 0.017).
Conclusions: The lowered SOCS1 mRNA levels in patients with less severe extra-pulmonary TB as compared to
those with more severe ETB and PTB may lead to elevated IFN-γ pathway gene expression in the latter group. As
localized ETB has shown to be associated with more effective Th1 immunity and adaptive responses, this suggests
a role for SOCS1 in determining disease outcome in extra-pulmonary TB.
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Background
In 2010 the Global Tuberculosis (TB) report indicated 8.8
million incident cases of TB with 1.1 million reported
deaths from TB amongst HIV-negative individuals [1]. In
Pakistan, the incidence of TB is 231/100,000 annually with
pulmonary TB (PTB) accounting for the majority of all TB
cases, while extra-pulmonary TB (ETB) contributes up to
18% of all TB cases [2].
Protection against M. tuberculosis infection is dependent
upon the interaction between host T cells and macro-
phages and is coordinated by cytokines. CD4+ T cells play
a central role in containment of M. tuberculosis infection
by secreting Interferon-gamma (IFN-γ) [3]. The enhanced
susceptibility to mycobacterial infection of IFN-γ knock-
out mice [4,5], and of patients with genetic defects in IL-
12/ IFN-γ pathway [6], provide strong evidence that IFN-γ
is required in defense against M. tuberculosis. Coordinated
Tumor necrosis factor alpha (TNF-α), and Interleukin-12
(IL-12) secretion by macrophages and dendritic cells res-
pectively, is required for protection against M. tuberculosis
[7]. It has been observed that IFN-γ responses in patients
with TB and further, pulmonary (PTB) patients with
far advanced disease are lowered as compared to those
with moderately advanced PTB cases [8]. Similarly,
patients with disseminated forms of extra-pulmonary
(ETB) disease such as miliary disease have defective IFN-γ
dependent responses as compared to patients with loca-
lized ETB such as, pleural TB [9]. IL-10 is a down-
regulatory cytokine which can balance the effect of IFN-γ
[10] and a decreasing IFN-γ/IL-10 ratio across the
spectrum of TB is associated with progressive disease [11].
Hence, the clinical severity of TB may be determined by
the regulatory balance between activating and inhibitory
cytokines in the host.
T regulatory cells (Tregs) are a sub-population of CD4 T
cells involved in inhibition of T cell responses and ‘FoxP3”
is a classical marker for these cells [12]. T regs are known
to secrete IL-10 and TGF-β which restrict T effector cell
responses [13]. Increase in CD4+CD25+ FoxP3+ cells has
been shown to decrease Th1 cell responses in patients with
TB [14].
Host gene expression profiling studies have identified
changes in genes regulating lymphocyte trafficking, growth
and proliferation and immune signaling pathways during
M. tuberculosis infection [15,16]. Expression levels of the
Suppressor of Cytokine Signaling (SOCS) molecules are
found to be raised in patients with active TB [17] and are
thought to play a role in regulation of cytokine secretion
and responses [18]. SOCS1 inhibits STAT1 activation and
thereby the response to IFN-γ. The importance of SOCS1
is illustrated by the death of SOCS1-/- mice within three
weeks after birth due to uncontrolled IFN-γ signaling [18].
SOCS3 another member of SOCS family, inhibits
STAT3 activation by gp130, a receptor chain of IL-6R
family molecules, amongst other receptors. SOCS3 is
preferentially expressed in Th2 cells and hampers the
differentiation of Th17 cells [19] and also attenuates the
anti-inflammatory effects of IL-6 in macrophages [20].
A differential cytokine activation profile has been asso-
ciated with the varying clinical severity of patients with TB
[21-23]. We hypothesized that the expression of SOCS1,
SOCS3 and FoxP3 affects both innate and adaptive im-
mune responses in patients with TB. Therefore, we studied
the expression of these molecules and of different cyto-
kines across a clinical spectrum of TB patients as com-
pared to that of EC by measuring their levels in both




Sixty six patients with TB were recruited from Aga Khan
University and Hospital (AKUH); Ojha Institute for Chest
Diseases, DOW University of Health Sciences (DUHS),
and Indus Hospital, Karachi using a cross-sectional study
design. The study was approved by Ethical Review Com-
mittees of the participating organizations and written
informed consent was obtained from all participants. Inclu-
sion criteria were: patients with a confirmed diagnosis of
TB who had not received anti-tuberculous therapy (ATT);
male or female; between 15–65 years of age; unrelated
study subjects. Exclusion criteria were: pregnancy; co-
morbid conditions (such as HIV infection, diabetes
mellitus, chronic renal failure, chronic liver disease or
corticosteroid therapy) and patients with relapsed TB.
Patients were classified as PTB and ETB as per WHO
guidelines for treatment of TB [24]. All PTB patients were
diagnosed by clinical examination, chest X-ray and had a
positive sputum acid-fast bacillus (AFB) microscopy and/
or AFB culture [25]. Severity of PTB was classified as
moderately advanced (PTB-mod) or far advanced (PTB-
adv) disease using a modified classification of the National
Tuberculosis Association of the USA based on extent of
lung tissue involvement [25]. All ETB patients were diag-
nosed by clinical examination, radiological imaging or a
positive histopathological staining result suggestive of
granulomatous inflammation of site specific biopsy or
FNAC (fine needle aspirate cytology). Severity of ETB was
also assessed by WHO guidelines for treatment of TB,
according to which cases with tuberculous lymphadenop-
athy and unilateral pleural effusion were classified as less-
severe ETB (L-ETB) and spinal, abdominal, ovarian and
bilateral pleural effusion TB were classified as severe disse-
minated ETB (D-ETB) [24].
Asymptomatic healthy volunteers who were BCG vacci-
nated staff at AKUH were recruited (EC, n = 15) after
tuberculin skin testing (TST). TST was assessed by intra-
dermal administration of five tuberculin units and read
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after 48 h. An induration of < 10 mm was used as a cut-off
for negative responses. Only TST negative EC were
selected as the un-infected control group for the study.
The age of TB patients and ECs was comparable
(mean ± SD; EC, 30.4 ± 10.1 y; TB, 31 ± 14.9 y) as was
their gender distribution (Male/Female; EC, 08/07; TB,
23/43). Characteristics of study subjects with PTB and
ETB and the specific disease site for each TB case is
listed in Table 1. Total leukocyte (TLC) counts and neu-
trophils were found to be significantly raised in all TB
groups as compared with EC, while lymphocyte counts
were reduced in the PTB and ETB groups as compared
with EC (Additional file 1: Table S1).
Mycobacterium culture
M. tuberculosis H37Rv (ATCC) was cultured in a 7H9
Middlebrook medium supplemented with 0.02%
glycerol, 10% albumin-dextrose-catalase Middlebrook
enrichment, and 0.5% Tween 80 (Difco Laboratories,
Detroit, MI) up to logarithmic phase. Aliquots of myco-
bacteria were frozen in growth medium containing 15%
glycerol and were stored at _70°C. For the infection
assay, aliquots of mycobacteria were freshly thawed,
washed three times in PBS, and diluted to MOI of 2.5.
Bacterial viability was greater than 80% in each case. To
prevent clumping of the mycobacteria, the cell suspen-
sion was sonicated prior to use as described previously
[26].
Infection of peripheral blood mononuclear cells (PBMCs)
with M. tuberculosis H37Rv
Ten ml of venous blood was used to obtain a buffy coat
layer containing peripheral blood mononuclear cells
(PBMCs) using Ficoll-histopaque density gradient.
PBMCs plated were 106 cells per well and were co-
incubated with M. tuberculosis H37Rv (ATCC) culture
at MOI-2.5. PBMCs were cultured for 18 hours in RPMI
1640 medium, L-glutamine 2 mM (Sigma Aldrich, USA)
with 10% autologous serum at 37°C after which cellular
supernatants were collected and total RNA was isolated
as described previously [27].
Real time PCR
Total RNA was isolated from PBMCs using Trizol reagent
(Invitrogen, USA). RNA (1 μg) was reverse transcribed
using MulV reverse transcriptase (Invitrogen, USA) as
described previously [28]. Real time PCR was performed
in duplicate 20 μl reactions containing PlatinumW SYBRW
Green qPCR Supermix-UDG (Invitrogen), 150 nM for-
ward and reverse primers, and 2 μl of cDNA on an ABI
PrismW 7500 sequence detection system (Applied Biosys-
tems, Foster City, CA). HuPO (human acidic ribosomal
protein) primer sequences were obtained from published
reports [29]. IFN-γ, SOCS1, SOCS3 and FoxP3 primer
sequences were designed using Primer Express software
(version 3.0, Applied Biosystems, Foster City, CA). Se-
quence specific primers used were
HuPO Forward 50-GCTTCCTGGAGGGTGTCC-30
HuPO Reverse 50GGACTCGTTTGTACCCGTTG-30








Table 1 Characteristics of the study subjects
Site N Abscess Microscopy Radiology AFBC Histopathology
PTB 33 14/23 30/30 10/16 2/23
ETB
L-ETB
Lymph Node 19 1 0/5 3/13 1/4 16/16
Unilateral Pleural 7 0/3 7/7 1/2 0/1
D-ETB
Spine 4 2 0/2 1/2 1/2 3/3
Abdominal 1 1/1 1/1 0/1 N/A
Ovarian 1 N/A 0/1 1/1 1/1
Bilateral Pleural 1 0/1 1/1 N/A N/A
PTB, pulmonary TB; ETB, extra-pulmonary TB; L-ETB, less severe ETB; D-ETB, disseminated ETB; N, number of subjects; Microscopy, acid fast bacillus smear using
Ziehl Neelsen staining; Radiology, XRay/ CT scan/ or MRI; AFBC, acid fast bacilli culture by MIGIT system (Becton Dickinson, USA); histo-pathological staining of
biopsy material and or FNAC (fine needle aspirate cytology) where relevant.
The numbers indicate those diagnosed as positive /of total by each method.
N/A, not available.
Masood et al. BMC Infectious Diseases 2013, 13:13 Page 3 of 9
http://www.biomedcentral.com/1471-2334/13/13
Two-fold dilutions of cDNA samples were amplified to
control amplification efficiency and to determine the opti-
mal concentration required for each primer pair. HuPO
was used as a control gene to calculate the ΔCt values for
individual samples. The relative amount of cytokine/ HuPO
transcripts was calculated using the 2-[ΔΔCt] method as
described [30]. These values were then used to calculate
the relative expression of cytokine mRNA in each of the
samples tested.
Measurement of Th1/Th2/Th17 cytokines
Cellular supernatants were collected for cytokine measure-
ments 18 hours post stimulation, spun to collect cellular
debris and stored at -70°C until tested. Concentrations of
IFN-γ, TNF-α, IL-2, IL-4, IL-6, IL-10 and IL-17 were mea-
sured in cell supernatants with a Th1/Th2/Th17 Human
Cytokine Flow Cytometric Bead Array kit (CBA) from BD
Biosciences Ca, USA as described previously [31].
Statistical analysis
Data is depicted as median values for each group with the
IQR (inter quartile range 25th to 75th percentile) indicated
in each case. Comparison of non-parametric data between
the groups was performed using the Mann–Whitney U,
Kruskal Wallis and Wilcoxon Rank non-parametric tests.
Analysis was performed and data plotted using GraphPad
PRISM Version 5 (GraphPad Software, San Diego, CA,
USA).
Results
Differential M. tuberculosis-induced SOCS1 in patients
with pulmonary and extra-pulmonary tuberculosis
We first compared the mRNA expression levels of
IFN-γ, SOCS1, SOCS3, and FoxP3 in peripheral blood cells
from patients with PTB, ETB and EC in either un-
stimulated cells or after stimulation with M. tuberculosis.
IFN-γ mRNA expression levels in un-stimulated and M.
Figure 1 Differential SOCS1 and FoxP3 gene expression in PTB and ETB. PBMCs from endemic controls (EC, n = 15) and TB patients
classified into pulmonary TB (PTB, n = 33) and extra-pulmonary TB (ETB, n = 33) patients were stimulated with M. tuberculosis H37Rv at MOI-2.5 for
18 hours. Total cellular RNA was harvested and subjected to RT-PCR. mRNA expression levels of IFN-γ, SOCS1, SOCS3 and FoxP3 genes from
individual subjects were determined. Box and whiskers plots indicate data between 10th- 90th percentiles with median values of each group
indicated by a horizontal line. Data shows (A) IFN-γ, (B) SOCS1, (C) SOCS3 and (D) FoxP3 mRNA expression in PBMCs. ‘*’ denotes significant
differences (p≤ 0.05) as compared with EC using Mann–Whitney U non-parametric test.
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tuberculosis stimulated PBMCs isolated from EC, PTB and
ETB groups were similar (Figure 1A). SOCS1 mRNA levels
were comparable in un-stimulated cells from EC, PTB and
ETB groups. However, M. tuberculosis -stimulated SOCS1
mRNA titers differed between EC, PTB and ETB groups
(p = 0.019, using Kruskal-Wallis ‘KW’ analysis). Further-
more, M. tuberculosis -induced SOCS1 mRNA titers were
higher in PTB as compared with EC (Mann Whitney-U test
‘MWU’ p = 0.0067, Figure 1B).
SOCS3 mRNA levels were comparable between EC, PTB
and ETB groups in un-stimulated and M. tuberculosis-
stimulated PBMCs (Figure 1C). However, we observed that
FoxP3 mRNA expression levels differed between un-
stimulated PBMCs from EC, PTB and ETB (KW p =
0.0035), whereby FoxP3 levels were raised in PTB (MWU
p= 0.014), and ETB (MWU p < 0.001) as compared with
ECs. In M. tuberculosis- stimulated cells, FoxP3 expression
levels were significantly higher in ETB (MWU p= 0.021) as
compared with EC, but not in the case of PTB (Figure 1D).
The direct effect of M. tuberculosis – stimulation was
studied by comparing mRNA expression titers for each
gene in un-stimulated and M. tuberculosis-stimulated
peripheral blood cells using the Wilcoxon rank test but
it was observed that there was no difference in the titers
of IFN-γ, SOCS1, SOCS3 or FoxP3. This may be due to
the already raised mRNA titers in TB patients as a con-
sequence of endogenous stimulation in the M. tubercu-
losis infected host.
Altered IFN-γ, IL-6 and IL-10 levels in tuberculosis
To further investigate the cytokine secretion profile in PTB
and ETB cases as compared with EC we measured IFN-γ,
TNF-α, IL-2, IL-4, IL-6, IL-10 and IL-17 in supernatants of
un-stimulated and M. tuberculosis – stimulated PBMCs.
IFN-γ, TNF-α, IL-2, IL-4 and IL-17 levels in supernatants
of un-stimulated cells from TB and EC groups were similar
(Table 2), whereas IL-6 levels were raised in PTB as com-
pared with EC (MWU p= 0.018). IL-10 levels were raised
in PTB (MWU, p = 0.013) and ETB (MWU, p = 0.003) as
compared with EC.
Subsequently, we measured M. tuberculosis-stimulated
cytokine secretions in each group. No differences were
Table 2 Increased TNFα, IL-6 and IL-10 with down-regulated IFN-γ in tuberculosis along with disease spectrum
Group Un-stimulated P value M. tuberculosis stimulated P value Δ MTB P value
Mean ± SD Mean ± SD Mean ± SD Mean ± SD
IFN-γ EC 0.09 ± 0.3 NS 73.61 ± 95.8 0.281 78.786 ± 97.1 NS
PTB 0 ± 0 18.889 ± 45.3 18.621 ± 45.4
ETB 0.83 ± 3.9 56.70 ±173.8 57.522 ± 176.4
TNFα EC 108.20 ± 134.7 NS 2541.29 ± 2877.2 0.573 2605.19 ± 2855.91 NS
PTB 535.81 ± 1082.35 2860.30 ± 3076.9 2378.4 ± 3146.84
ETB 340.02 ± 358.92 2056.48 ± 2005.8 1696.79 ± 2045.4
IL-2 EC 0.109 ± 0.4 NS 24.15 ± 53.9 0.249 24.045 ± 53.92 NS
PTB 0.148 ± 0.51 23.18 ± 99.28 21.507 ± 97.6
ETB 0.098 ± 0.404 36.87 ± 143.21 31.84 ± 134.92
IL-4 EC 0 ± 0 NS 0 ± 0 0.762 0 ± 0 NS
PTB 0.083 ± 0.42 0.039 ± 0.2 0.37 ± 0.19
ETB 0.375 ± 0.212 0.049 ± 0.288 0.049 ± 0.29
IL-6 EC 651.13 ± 1018.2 0.054 10804.35 ± 1301.5 0.215 11041.6 ± 9963.4 0.02
PTB 6968.3 ± 8592.02* 11782.32 ± 9677.6 7125.8 ± 9578.9
ETB 4677.9 ±5490.6 6581.54 ± 4757.47 2642.01 ± 3864.3*
IL-10 EC 0.29 ± 1.1 0.011 84.78 ± 168.3 0.874 90.54 ± 171.94 NS
PTB 55.75 ± 234.4* 76.285 ± 217.01 42.758 ± 106.81
ETB 51.33 ±169.17* 47.85 ± 91.7 24.76 ± 73.81
IL-17 EC 0 ± 0 NS 0 ± 0 1 0 ± 0 NS
PTB 0.075 ± 0.38 0 ± 0 0 ± 0
ETB 0 ± 0 0 ± 0 0 ± 0
EC, endemic control (n = 15); PTB, pulmonary TB (n = 33); ETB, extra-pulmonary TB (n = 33).
IQR, interquartile range between 25th and 75th percentile.
* Denotes significant difference (p ≤ 0.05) as compared with EC using Mann–Whitney U non-parametric test.
P value calculated using Kruskal Wallis test. NS denotes non-significant P value (p > 0.05).
Δ is calculated by substracting M. tuberculosis stimulated cytokine levels from background levels from un-stimulated cells.
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observed in response to M. tuberculosis in IFN-γ, TNF-
α, IL-2, IL-4, IL-10 and IL-17 secretion between EC,
PTB and ETB groups (Table 2). M. tuberculosis-induced
IL-6 (MWU p = 0.003) was reduced in ETB as compared
with EC.
Differential M. tuberculosis induced SOCS1 expression
with varying severity of tuberculosis
Since SOCS1 and FoxP3 gene expression levels differed
between PTB and ETB groups we further investigated
whether they associated with the clinical severity. There-
fore, we compared gene expression levels between mod-
erately advanced (PTB-mod) and far advanced (PTB-
adv) PTB, less severe (L-ETB) and more severe (D-ETB)
ETB cases with ECs. In un-stimulated cells, SOCS1
mRNA levels were raised in PTB-adv as compared with
PTB-mod (MWU p = 0.008) and EC (p = 0.034).
FoxP3 mRNA levels were significantly higher in
PTB-adv (MWU p = 0.002), L-ETB (MWU p = 0.002)
and D-ETB (MWU, p = 0.018) as compared with EC. There
was no difference between IFN-γ and SOCS3 mRNA ex-
pression titers between un-stimulated cells of the TB and
EC groups studied (Additional file 2: Table S2).
We then compared M. tuberculosis-stimulated responses
in the study subjects. IFN-γ mRNA levels did not differ
between the groups studied (Figure 2A). However, M.
tuberculosis induced SOCS1 mRNA gene expression
levels were raised in PTB-mod (MWU, p = 0.022), PTB-
adv (MWU, p = 0.014) and D-ETB (MWU, p = 0.009)
groups as compared with EC (Figure 2B). Further, M.
tuberculosis-stimulated SOCS1 mRNA titers were signifi-
cantly greater in PTB-adv (MWU, p = 0.016) and D-ETB
groups (MWU, p = 0.027) as compared with L-ETB
(Figure 2B). M. tuberculosis –induced SOCS3 mRNA
expression was reduced in PTB-adv (MWU, p = 0.007) as
compared with EC (Figure 2C). M. tuberculosis –induced
FoxP3 mRNA expression levels showed a higher accu-
mulation in PBMCs from L-ETB (MWU, p = 0.017) as
compared with EC (Figure 2D).
Figure 2 Differential M. tuberculosis induced SOCS1 and SOCS3 expression with varying severity of tuberculosis. PBMCs from endemic
controls (EC, n = 15) and moderately advanced PTB (PTB-mod, n = 20), far advanced PTB (PTB-adv, n = 13), less severe ETB (L-ETB, n = 26) and
severe ETB (D-ETB, n = 7) patients were stimulated with M. tuberculosis H37Rv at MOI-2.5 for 18 hours. Total cellular RNA was harvested and
subjected to RT-PCR. mRNA expression levels of IFN-γ, SOCS1, SOCS3 and FoxP3 genes from individual subjects are depicted as scatter plots for
each group with median values indicated by a horizontal line. Data shows (A) IFN-γ, (B) SOCS1, (C) SOCS3 and (D) FoxP3 mRNA expression in
PBMCs. ‘#’ denotes significant differences (p ≤ 0.05) as compared with EC, ‘*’ denotes significant differences (p ≤ 0.05) between PTB-adv, L-ETB and
D-ETB group using Mann–Whitney U non-parametric test.
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Discussion
Th1 immune responses (IFN-γ, IL-12) are required for
protection against infection with M. tuberculosis while a
raised Th2-like cytokine profile (such as, IL-10, IL-4 and
TGF-β) is implicated with disease progression in TB. To
our knowledge, this is the first study to show an associ-
ation between cytokine profiles in TB with the differen-
tial expression of SOCS1, SOCS3 and FoxP3 molecules
in PTB and ETB. All SOCS1 and FoxP3 mRNA levels
and IL-6 and IL-10 protein titers were increased in PTB.
SOCS1 and FoxP3 mRNA and IL-10 protein titers were
also raised in ETB. Further M. tuberculosis- stimulated
moderate ETB showed decreased SOCS1 as compared
with both severe ETB and far advanced PTB cases.
The raised IL-6 levels could also contribute to the
increased SOCS1 expression in PTB. IL-6 might in-
hibit Th1 type cell responses by hampering IFN-γ,
TNF-α and IL1β responses [32]. IL-10 is now recog-
nized to be produced by almost every type of cell of
the immune system, including most lymphocyte
populations and cells of the innate immune system,
such as antigen-presenting cells (DCs and macro-
phages) and granulocytes [33]. In murine models,
increased IL-10 hampers protective anti- M. tubercu-
losis T cell responses [34]. IL-10 levels in peripheral
blood cells and serum of active pulmonary TB
patients were shown to be raised [35]. High IL-10
levels in both PTB and ETB were associated with an
increase in FoxP3 expression. We observed FoxP3 gene
expression and IL-10 secretion to be increased in both
PTB and ETB compared to EC. The secretion of IL-10 by
Tregs can account for the inhibition of T cell responses
[36]. Neutralization of endogenous IL-10 in PBMCs from
pulmonary TB patients resulted in increased T-cell prolif-
eration and IFN-γ production [33], with enhanced prolif-
erative responses to PPD in patients with anergic TB [37].
Thus, increased IL-10 levels in TB patients may hinder T
cell responses.
M. tuberculosis –induced IL-6 and IL-10 levels in ETB
were reduced as compared with EC. The reduced re-
sponsiveness of cells from M. tuberculosis-infected indi-
viduals with advanced disease is in line with previous
reports which demonstrate raised endogenous levels of
IL-8 and reduced Mycobacterium-stimulated IL8 in
patients with advanced leprosy disease [38].
We measured all the cytokines simultaneously after
18 h of culture. This time point has been found to
be suitable for measuring most cytokines [39] except
IFN-γ responses which are increased in up to 6 days
of culture [40]. Therefore it may be that we have
underestimated the IFN-γ levels in our study.
All TB patients showed an increased total leukocyte
but decreased lymphocyte numbers as compared with
the control group. The increased SOCS1 mRNA
expression observed in these patients despite a reduced
lymphocyte count could be attributed to SOCS1 expres-
sion from macrophages [41,42]. We previously demon-
strated that an increased SOCS1 mRNA expression
associates with clinical severity in PTB patients [28].
Here we show that post M. tuberculosis stimulation,
SOCS1 levels were lower in cases with less severe ETB
as compared with more severe ETB and also as com-
pared with advanced PTB. Previous studies have shown
that mycobacterial antigen specific IFN-γ levels are high-
est in the L-ETB group [43] as compared with other
sites. As SOCS1 impacts IFN-γ regulation [44], the
reduced SOCS1 expression in less severe ETB group
may indicate more effective T effector cell responses
leading to protective granuloma formation in these
cases. These data fit with previous studies that have
shown higher IFN-γ responses in patients with pleural
TB than those with miliary disease [9]. Also that in
patients with tuberculous lymphadenitis IFN-γ responses
are raised as compared to those with severe dissemi-
nated ETB [27].
M. tuberculosis stimulated SOCS3 mRNA levels were
lower in PTB-adv as compared with EC. Loss of SOCS3
expression in macrophages is associated with reduced
IL-12 and TNF levels [45]. Therefore, decreased SOCS3
expression in PTB-adv patients may contribute to an
impaired bactericidal response to M. tuberculosis.
Conclusions
Our results show differential expression of SOCS1
and FoxP3 together with variable IL-10 and IL-6 se-
cretion in PTB and ETB. In addition, we observed
an association between reduced SOCS1 expression
and more localized ETB. These data suggest that the
balance between these cytokines and SOCS1 may de-
termine the dysregulation of immune balance in the
host thereby affecting clinical severity of disease.
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